Skip to content

Anti-Gelsolin-3 Antibody Validation and Clinical Phenotyping in Facial Palsy: A Multicenter Study in China

Anti-Gelsolin-3 Antibody Validation and Clinical Phenotyping in Facial Palsy: A Multicenter Study in China

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600122939
Enrollment
Unknown
Registered
2026-04-20
Start date
2026-04-20
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Facial neuritis

Interventions

Anti gelsolin-3 IgG positive group and anti gelsolin-3 IgG negative group:No

Sponsors

Affiliated Hospital of Jining Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Clinically diagnosed with facial neuritis (idiopathic facial palsy), presenting with acute-onset unilateral or bilateral facial motor dysfunction; 2. Aged >= 14 years; 3. Onset of symptoms within 2 weeks; 4. The patient or their family member has provided informed consent and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Confirmed secondary facial palsy (e.g., due to herpes zoster, otitis media, tumor, trauma, etc.); 2. Prior history of immune-mediated neuropathies such as GBS, MFS, or CIDP; 3. Concomitant severe cardiac, hepatic, or renal insufficiency, or malignancy; 4. Complicated by diabetes mellitus; 5. Pregnant or breastfeeding women.

Design outcomes

Primary

MeasureTime frame
Anti gelsolin-3 IgG;Facial nerve function score;Electrophysiological characteristics;

Countries

China

Contacts

Public ContactYuzhong Wang

Affiliated Hospital of Jining Medical University

wangyuzhong_ni@163.com+86 186 7876 1163

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 1, 2026